Azapropazone

Oral
Acute gout

Oral
Ankylosing spondylitis, Rheumatoid arthritis

CrCl (mL/min)	Dosage
<50	Reduce dose by one-half to two-thirds.
50-75	Reduce dose by one-third to one-half.

Should be taken with food. Take w/ or immediately after meals.

History of peptic ulceration, porphyria, inflammatory bowel disease, blood disorders, hypersensitivity. Not to be used in acute gout of elderly with even mild renal function. Lactation. Severe renal disease.

Allergic disorders, coagulation defects; renal, cardiac or hepatic impairment; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, pregnancy. Should be withdrawn if GI lesions develop. Long-term use of NSAID is associated with reversible, reduced female fertility. Maintain adequate fluid intake.

GI disorders; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity, haematuria; blood disorders, fluid retention, hypertension.

Enhances effects of oral anticoagulants (warfarin), phenytoin and sulfonylureas. Increased plasma concentration of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity when used with ACE inhibitors, cyclosporin, tacrolimus or diuretics; hypokalaemia may also result from ACE inhibitors and diuretics concomitant use. Quinolones may produce convulsions. Moclobemide enhances NSAIDs effects. Increased risk of adverse reactions with other NSAIDs. Increased risk of GI bleeding and ulceration with corticosteroids, SSRIs, clopidrogel and ticlopidine, biphosphonates or pentoxifylline; haemotoxicity with zidovudine. Ritonavir increases plasma concentration; mifepristone and antihypertensives alter the drug's efficacy.

Description:
Mechanism of Action: Azapropazone is an NSAID structurally related to phenylbutazone which also has uricosuric properties.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)